High Response Rate to Carboplatin-Paclitaxel-Cetuximab and Pembrolizumab in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Case Rep Oncol. 2023 Jan 16;16(1):13-20. doi: 10.1159/000528326. eCollection 2023 Jan-Dec.
Case Rep Oncol. 2023.
PMID: 36743882
Free PMC article.